Lundbeck’s asedebart receives EC orphan designation in Cushing’s syndrome
Asedebart is a humanised anti-ACTH monoclonal antibody that blocks ACTH binding to melanocortin 2.
Drug Development
Takeda’s Orzeyful secured Japan MHLW approval for narcolepsy type 1
Gossamer Bio announces $250m in funding to advance seralutinib
WellSpan and Johns Hopkins renew partnership for advanced cancer care access
Charles River and MVC to develop enterovirus vaccine
FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy
SandboxAQ introduces AQPotency for virtual drug screening
Andelyn Biosciences to develop GM2 gangliosidosis therapy
